undamentalytics Newsletter
Sign in

Alignment Healthcare, Inc. (ALHC) stock

Add to watchlist

Add holding +

NASDAQ: ALHC Nasdaq Managed Health Care Next results ~January 28, 2027

D Fundamentals grade

Alignment Healthcare, Inc. is a US-listed company in the managed health care industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.4

Forward price-to-earnings vs peers

Base case. Range ~$8.4–$13. Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Alignment Healthcare, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 11 selling1 purchase and 79 sales by directors and officers, last 12 monthsInsider trades
  • Funds216 adding, 125 cuttingOf 65 active managers that changed their stake, 33 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Alignment Healthcare files

10-Q filed October 29: Alignment Healthcare

Model value −3.0%

Alignment Healthcare posted revenue of $4.94bn for the twelve months to September 2026, up 35.9% on a year earlier. That pace has eased from the 37.2% growth recorded a quarter earlier, suggesting the top line is beginning to moderate. Despite the slowdown, the fundamentals grade has improved, moving from E to D. Our model value, however, has drifted lower, slipping from $9.68 to $9.39 a share. Against this, the shares trade at $8.26, leaving them below our latest estimate of fair value. Taken together, the figures point to a business still growing briskly but doing so at a gentler rate than before, with valuation measures adjusting accordingly.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Alignment Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $4.58bn, up 37.2% on a year earlier, slower than the 41.8% growth a quarter earlier. The diluted share count is up 3.9% on a year earlier, which dilutes existing holders. Our forward price-to-earnings vs peers value is $9.68 a share, against a share price of $7.88.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 28, 2027 (estimated)

Alignment Healthcare, Inc.'s trailing-twelve-month revenue grew 35.9% year on year, with a free-cash-flow margin of 1.6%. Where it lags: long-term debt as % of assets of 25.0% ranks 7 of 7 managed health care companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 35.9% (-1.3pp vs the prior quarter), the 5th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 35.9% over the last 12 months, against a median of 18.3% for managed health care companies we cover.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • High earnings multiple. The shares trade at 49 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 70% and a beta of 0.4 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 25.0% ranks 7 of 7 managed health care companies we cover (median 22.4%).
  • Below peers: stock pay as % of revenue. Stock pay as % of revenue of 1.3% ranks 7 of 8 managed health care companies we cover (median 0.2%).
  • Heavily shorted. 12.6% of the shares available to trade are sold short (1.8 days of average volume to cover).
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 10.0% over 90 days.

Latest results: FY2026 Q3

Filed October 29, 2026
Earnings per share
$0.05 against an average estimate of $0.04: beat by 5.9%
Revenue
$1.36bn, up 36.7% on a year earlier
Share reaction
-11.1% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Guidance given
health Plan Membership 305000 (Three Months Ending December 31, 2026); health Plan Membership 305000 (Twelve Months Ending December 31, 2026)
Next report
October 29, 2026; average EPS estimate $0.04

Alignment Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.7%
  • 1 week-11.3%
  • 1 month-11.8%
  • This year-64.6%
  • 1 year-58.5%
  • 5 years-65.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.9B
Operating margin
0.9%
Net margin
0.6%
EPS (TTM, diluted)
$0.14

Growth

Revenue growth
+35.9%
Change in growth rate
−1.3 pts
Share count change
+1.6%

Earnings

Last results
October 29, 2026
Next results (est.)
January 28, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Announcement
  4. Insider trade
  5. Insider trade
  6. Insider trade
  7. Insider trade
  8. Results
  9. Insider trade
  10. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Alignment Healthcare, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Alignment Healthcare, Inc. as a health plan, with every model that fits that kind of business. Cost of equity 7.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.51 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.4 ~$8.4–$13 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (forward price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.4 ~$8.4–$13 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Alignment Healthcare, Inc. with health plans in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.45 +41% $5.2bn +32%
Next $0.65 +44% $6.5bn +25%

Next year's EPS estimate has moved −10.0% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −4.7% on 90 days ago. In the last 30 days, 0 analysts raised Alignment Healthcare, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Alignment Healthcare, Inc., last 90 days
$0.40 $0.50 $0.60 $0.70 $0.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.47 Current fiscal year, 60 days ago: $0.49 Current fiscal year, 30 days ago: $0.49 Current fiscal year, 7 days ago: $0.49 Current fiscal year, Now: $0.45 $0.45 Next fiscal year, 90 days ago: $0.72 Next fiscal year, 60 days ago: $0.75 Next fiscal year, 30 days ago: $0.75 Next fiscal year, 7 days ago: $0.75 Next fiscal year, Now: $0.65 $0.65

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.47$0.72
60 days ago $0.49$0.75
30 days ago $0.49$0.75
7 days ago $0.49$0.75
Now $0.45$0.65

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.04 $0.05 +5.9%
Jun 2026 $0.20 $0.25 +24.4%
Mar 2026 $0.09 $0.12 +38.7%
Dec 2025 −$0.08 −$0.00 +98.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 29, 2026
  • Health Plan Membership Twelve Months Ending December 31, 2026 about 305,000 Raised
    “Health Plan Membership 305,000 305,000” source
  • Health Plan Membership Three Months Ending December 31, 2026 about 305,000 New
    “Health Plan Membership 305,000 305,000” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

15 analysts, Oct 2026
Buy1067%
Hold533%
Sell00%

Monthly trend

  1. Oct 202637515
  2. Sep 202639214
  3. Aug 202639214
  4. Jul 2026210214

Counts of recommendations published by analysts covering Alignment Healthcare, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
12.6%
of tradable shares
Days to cover
1.84
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
2.6%
of shares
Employees
1,849
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −58.5%

$16.86 on October 31, 2025 to $7.00

ThenNowEffect
Revenue (last 12 months) $3.3bn $4.6bn +37.2%
P/S multiple 1.0x 0.3x −68.6%
Share count 197m 204m −3.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
ALHC−16%−27%+31%+76%−65%
Industry peers (median)+4%+1%−18%−25%+62%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
ALHC67%42%58%58%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
ALHC−54%−60%−50%−41%−72%
S&P 500−25%−10%−8%−19%−9%

Worst fall since March 26, 2021: 84% from June 21, 2021 to April 3, 2024. Getting back needed a 510% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.00 – $24.56
From 52-week high
−71.5%
vs 50-day average
−28.2%
vs 200-day average
−58.2%
Volatility (1 year)
70%
Beta vs S&P 500
0.44

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±11.4%
After a week
4 up, 7 down
typical move ±15.3%
After a month
6 up, 5 down
typical move ±24.3%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 −11.1% −2.1% — —
July 30, 2026 −18.8% +2.4% −26.8% −25.5%
April 30, 2026 −6.7% +1.3% −16.0% −38.8%
February 26, 2026 −4.5% −1.0% −7.7% −17.4%
October 30, 2025 −7.4% −0.8% −9.4% +4.8%
July 30, 2025 +17.0% −0.5% +16.4% +38.5%
May 1, 2025 −12.4% +2.2% −13.0% −12.5%
February 27, 2025 +19.2% −0.1% +15.9% +39.1%
October 29, 2024 +1.6% −0.1% +15.1% +11.2%
August 1, 2024 +2.3% −3.3% −3.7% +3.1%
May 2, 2024 +27.0% +2.2% +32.4% +53.1%
February 27, 2024 −8.9% +0.1% −11.9% −22.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Alignment Healthcare, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Alignment Healthcare, Inc.
$1B $2B $3B $4B $5B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $1.8B Revenue (TTM), FY24 Q1: $2B Revenue (TTM), FY24 Q2: $2.2B Revenue (TTM), FY24 Q3: $2.5B Revenue (TTM), FY24 Q4: $2.7B Revenue (TTM), FY25 Q1: $3B Revenue (TTM), FY25 Q2: $3.3B Revenue (TTM), FY25 Q3: $3.6B Revenue (TTM), FY25 Q4: $3.9B Revenue (TTM), FY26 Q1: $4.3B Revenue (TTM), FY26 Q2: $4.6B Revenue (TTM), FY26 Q3: $4.9B $4.9B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $1.8B
FY24 Q1 $2B
FY24 Q2 $2.2B
FY24 Q3 $2.5B
FY24 Q4 $2.7B
FY25 Q1 $3B
FY25 Q2 $3.3B
FY25 Q3 $3.6B
FY25 Q4 $3.9B
FY26 Q1 $4.3B
FY26 Q2 $4.6B
FY26 Q3 $4.9B
Revenue growth, TTM YoY Alignment Healthcare, Inc.
20% 30% 40% 50% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 27.2% Revenue growth, TTM YoY, FY24 Q1: 31.8% Revenue growth, TTM YoY, FY24 Q2: 37.5% Revenue growth, TTM YoY, FY24 Q3: 43.5% Revenue growth, TTM YoY, FY24 Q4: 48.3% Revenue growth, TTM YoY, FY25 Q1: 49.1% Revenue growth, TTM YoY, FY25 Q2: 49.5% Revenue growth, TTM YoY, FY25 Q3: 47.4% Revenue growth, TTM YoY, FY25 Q4: 46.1% Revenue growth, TTM YoY, FY26 Q1: 41.8% Revenue growth, TTM YoY, FY26 Q2: 37.2% Revenue growth, TTM YoY, FY26 Q3: 35.9% 35.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 27.2%
FY24 Q1 31.8%
FY24 Q2 37.5%
FY24 Q3 43.5%
FY24 Q4 48.3%
FY25 Q1 49.1%
FY25 Q2 49.5%
FY25 Q3 47.4%
FY25 Q4 46.1%
FY26 Q1 41.8%
FY26 Q2 37.2%
FY26 Q3 35.9%
Operating margin (TTM) Alignment Healthcare, Inc.
-10% -5% 0% 5% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -7.0% Operating margin (TTM), FY24 Q1: -6.8% Operating margin (TTM), FY24 Q2: -5.9% Operating margin (TTM), FY24 Q3: -4.9% Operating margin (TTM), FY24 Q4: -3.8% Operating margin (TTM), FY25 Q1: -2.2% Operating margin (TTM), FY25 Q2: -0.7% Operating margin (TTM), FY25 Q3: 0.1% Operating margin (TTM), FY25 Q4: 0.4% Operating margin (TTM), FY26 Q1: 0.8% Operating margin (TTM), FY26 Q2: 1.2% Operating margin (TTM), FY26 Q3: 0.9% 0.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -7.0%
FY24 Q1 -6.8%
FY24 Q2 -5.9%
FY24 Q3 -4.9%
FY24 Q4 -3.8%
FY25 Q1 -2.2%
FY25 Q2 -0.7%
FY25 Q3 0.1%
FY25 Q4 0.4%
FY26 Q1 0.8%
FY26 Q2 1.2%
FY26 Q3 0.9%
FCF margin (TTM) Alignment Healthcare, Inc.
-10% -5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -5.2% FCF margin (TTM), FY24 Q1: -9.5% FCF margin (TTM), FY24 Q2: -9.3% FCF margin (TTM), FY24 Q3: -7.6% FCF margin (TTM), FY24 Q4: -0.2% FCF margin (TTM), FY25 Q1: 0.6% FCF margin (TTM), FY25 Q2: 0.9% FCF margin (TTM), FY25 Q3: 4.1% FCF margin (TTM), FY25 Q4: 2.9% FCF margin (TTM), FY26 Q1: 5.3% FCF margin (TTM), FY26 Q2: 3.9% FCF margin (TTM), FY26 Q3: 1.6% 1.6%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -5.2%
FY24 Q1 -9.5%
FY24 Q2 -9.3%
FY24 Q3 -7.6%
FY24 Q4 -0.2%
FY25 Q1 0.6%
FY25 Q2 0.9%
FY25 Q3 4.1%
FY25 Q4 2.9%
FY26 Q1 5.3%
FY26 Q2 3.9%
FY26 Q3 1.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 757 959 1,168 1,434 1,824 2,704 3,949 4,942
EBITDA −15 10 −162 −111 −106 −75 45 75
Operating income −29 −5 −178 −129 −128 −102 15 44
Net income −45 −23 −195 −150 −148 −128 −1 29
Diluted EPS −$0.03 −$0.01 −$1.14 −$0.83 −$0.79 −$0.67 $0.00 $0.14
Growth (year on year)
Revenue — +26.7% +21.7% +22.8% +27.2% +48.3% +46.1% +35.9%
Margins
EBITDA margin −1.9% 1.0% −13.9% −7.8% −5.8% −2.8% 1.1% 1.5%
Operating margin −3.9% −0.5% −15.2% −9.0% −7.0% −3.8% 0.4% 0.9%
Net margin −5.9% −2.4% −16.7% −10.4% −8.1% −4.7% −0.0% 0.6%
Free-cash-flow margin — — — −4.8% −5.2% −0.2% 2.9% 1.6%
Cash flow
Cash from operations 9 8 −79 −45 −59 35 140 108
Capital spending — — — 24 36 41 27 31
Free cash flow — — — −69 −95 −7 113 77
Stock-based pay 0 0 1 82 67 71 62 63
Free cash flow after stock pay — — — −151 −162 −78 51 14
Balance sheet
Cash 86 207 467 410 203 433 576 728
Total debt 0 150 154 165 165 330 330 330
Net debt (negative = net cash) −86 −57 −312 −245 −38 −103 −246 −398
Diluted shares — — 182m 181m 186m 191m 198m 204m
Returned to shareholders
Buybacks 2 2 1 0 0 — — —
Total returned 2 2 1 0 0 — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+1.6%
year over year
Sales & admin spending
10.4%
of revenue
Days sales outstanding
18 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in managed health care
Last 12 months unless stated ALHC CLOV OSCR MOH HUM ELV Median
Revenue, last 12 months $4.9bn $2.5bn $15.3bn $44.1bn $145.7bn $201.8bn $94.9bn
Revenue growth, last 12 months 35.9% 54.0% 42.8% −0.9% 18.3% 3.6% 14.0%
Revenue growth, 3-year average 42.2% 420.1% 45.6% 9.9% 13.8% 6.2% 12.3%
Revenue growth, latest quarter 36.7% 55.6% 70.4% −3.4% 26.2% 1.4% 14.1%
Gross margin — 24.9% — 12.6% — 89.0% 24.9%
Operating margin 0.9% −0.7% 4.1% 0.4% 1.9% 2.7% 1.4%
Operating margin, 3-year average −1.3% −4.0% 1.2% 2.5% 2.5% 3.8% 1.8%
Net margin 0.6% −0.7% 3.6% −0.1% 0.9% 2.5% 0.8%
Cash from operations / revenue 2.2% 3.1% 28.8% 0.8% 1.7% 3.8% 2.7%
Free-cash-flow margin 1.6% 3.0% 28.6% 0.5% 1.3% 3.2% 2.5%
Free-cash-flow margin, 3-year average −0.6% −5.2% 14.4% −0.2% −0.4% 1.9% 0.6%
Stock pay / revenue 1.3% 2.9% 0.5% 0.2% 0.2% 0.1% 0.2%
Change in share count 1.6% 6.8% 12.1% −6.1% 0.1% −3.3% −0.2%

Median of all 8 companies we cover in managed health care. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

8 managed health care companies
Measure Company Peer median Rank
Revenue growth Growth 35.9% 18.3% 3 of 8
Change in growth rate Growth -1.3pp -1.3pp 4 of 8
Operating margin Profitability 0.9% 1.9% 5 of 8
Net margin Profitability 0.6% 0.9% 6 of 8
Stock pay as % of revenue Cash generation 1.3% 0.2% 7 of 8
Long-term debt as % of assets Balance sheet 25.0% 22.4% 7 of 7
Change in share count Balance sheet 1.6% 0.1% 6 of 8

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$5.3B
Institutions reporting
321
Shares held vs prior quarter
▲ 10.3%
Positions opened / closed
74 / 45

Top buyers and sellers, Q2 2026: 216 institutions bought and 125 sold ; the biggest buyer was Bank Of America Corp (+6.1M shares) and the biggest seller Citadel Advisors LLC (−5.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $461M 19.3M 8.7% ▲ 37.4%
Wellington Management Group LLP $447M 18.8M 8.4% ▲ 9.8%
FMR LLC $332M 13.9M 6.3% ▼ 12.4%
T. Rowe Price Investment Management, Inc. $312M 13.1M 5.9% ▼ 0.2%
Vanguard Portfolio Management LLC $278M 11.7M 5.3% ▲ 20.2%
Invesco Ltd. $247M 10.4M 4.7% ▲ 48.1%
Bank Of America Corp $223M 9.3M 4.2% ▲ 190.7%
Vanguard Capital Management LLC $194M 8.1M 3.7% ▲ 2.1%
William Blair Investment Management, LLC $185M 7.8M 3.5% ▲ 48.8%
State Street Corp $174M 7.3M 3.3% ▲ 70.0%
Hood River Capital Management LLC $147M 6.2M 2.8% ▲ 2.1%
Price T Rowe Associates Inc $118M 4.9M 2.2% ▼ 14.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Alignment Healthcare, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $197,627 1 trade by 1 insider, last 12 months Insider sales History → $521M 79 trades by 11 insiders · 16% under pre-set plans
Net ▼ $520M net selling
Insider Date Trade Shares Price Value
Kim Hyong Chief Medical Officer October 6, 2026 Sell 32,479 $8.30 $269,576
Konowiecki Joseph S EVP, Corporate Affairs September 17, 2026 Sell 23,511 $8.61 $202,430
Kao John E Chief Executive Officer September 14, 2026 Sell pre-set plan 27,400 $13.00 $356,200
Kao John E Chief Executive Officer September 11, 2026 Sell pre-set plan 385,270 $12.68 $4.9M
Maroney Dawn Christine President September 11, 2026 Sell 122,707 $12.68 $1.6M
Kao John E Chief Executive Officer September 10, 2026 Sell pre-set plan 172,600 $12.96 $2.2M
Maroney Dawn Christine President August 14, 2026 Sell pre-set plan 5,000 $14.00 $70,000
Kao John E Chief Executive Officer August 10, 2026 Sell pre-set plan 298,000 $13.88 $4.1M
Maroney Dawn Christine President July 15, 2026 Sell pre-set plan 177,068 $20.83 $3.7M
Kao John E Chief Executive Officer July 10, 2026 Sell pre-set plan 18,356 $20.65 $379,051
Kao John E Chief Executive Officer July 10, 2026 Sell pre-set plan 279,644 $19.81 $5.5M
Konowiecki Joseph S EVP, Corporate Affairs July 1, 2026 Sell pre-set plan 25,000 $24.00 $600,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 28, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • July 30, 2026
  • April 30, 2026
  • February 26, 2026
  • October 30, 2025
  • July 30, 2025

Recent SEC filings

Data status

When each part of this page on Alignment Healthcare, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Alignment Healthcare, Inc. in brief

What does Alignment Healthcare, Inc. do?
Alignment Healthcare, Inc. is a US-listed company in the managed health care industry. Its financial year ends in December.
What is Alignment Healthcare, Inc.'s stock ticker?
Alignment Healthcare, Inc. trades under the ticker ALHC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Alignment Healthcare, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Alignment Healthcare, Inc. reported revenue of $4.9B, 35.9% higher than a year earlier, according to its SEC filings.
What is Alignment Healthcare, Inc.'s free cash flow?
Alignment Healthcare, Inc.'s free-cash-flow margin is 1.6% of revenue over the trailing twelve months.
Who are Alignment Healthcare, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Wellington Management Group LLP and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Alignment Healthcare, Inc.'s market cap?
On November 2, 2026, Alignment Healthcare, Inc.'s market capitalisation was about $1.4B, with a price-to-earnings ratio of 49.4 and net debt of -$398M. Market figures come from third-party market data and may be delayed.
Who are Alignment Healthcare, Inc.'s competitors?
In our Managed Health Care peer group, the companies closest to Alignment Healthcare, Inc. are Clover Health Investments, Corp., Oscar Health, Inc., Molina Healthcare, Inc., Humana and Elevance Health. The side-by-side comparison below sets their revenue, margins and growth against Alignment Healthcare, Inc.'s.
Are insiders buying or selling Alignment Healthcare, Inc. stock?
Over the last 12 months, Alignment Healthcare, Inc.'s directors and officers reported 1 open-market purchases and 79 sales on Form 4. The insider trading page charts every trade.
When is Alignment Healthcare, Inc.'s next earnings date?
Around January 28, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Alignment Healthcare, Inc. announces its own schedule.